Mehmet Turgut

Mehmet Turgut

Auto-generated profile, based on publicly available information

Mehmet Turgut


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2020 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
EAElifcan Aladag
Elifcan Aladag
HDHaluk Demi̇rOğlu
Haluk Demi̇rOğlu
YBYahya Büyükaşik
Yahya Büyükaşik
MTMehmet Turgut
Mehmet Turgut
SASalih Aksu
Salih Aksu
HGHakan Göker
Hakan Göker
High-dose melphalan and autologous hematopoietic stem cell transplantation (AHSCT) is the standard treatment strategy in Multiple Myeloma (MM) patients who are eligible for AHSCT. The recommended dose of CD34+ hematopoietic progenitor cells (HPC) for adequate engraftment is above 2 x 106/kg.. The aim of this study is to evaluate the relationship between CD34+ HPC dose and the survival in MM patients who underwent AHSCT at our tertiary care center. 271 MM patients, who underwent AHSCT between 2003-2019, were enrolled in this study. Clinical characteristic of patients, disease status pre-AHSCT, re-infused CD34+ cell doses, neutrophil and platelet engraftment days were recorded, retrospectively. The patients were divided into two groups according to whether re-infused CD 34+ HPC dose were < 5 x 106 /kg or ? 5 x 106 /kg. The groups were compared in terms of engraftment and overall survival times. The median age of all patients was 54.8 (33 - 76) years. The median CD34+ HPC dose infused was 5.94 x 106/kg (1.47 - 59.5 x 106/kg). The median follow-up period was 54 months (4-211). The median overall survival of all patients was 103 months (11-144). Median neutrophil and platelet engraftment time was 10 (8-24) and 11 (7-40) days, respectively. < 5 x 106/kg and ? 5 x 106/kg CD34+ HPC were reinfused 38,1% and 61.9% of the patients, respectively. There was a negative significant correlation between reinfused CD34+ cell level and neutrophil/platelet engraftment times (r: -0.32, p= <0.001; r: -0.27, p= <0.001, respectively). The median overall survival times were observed as 103 months (11-144) and 145 months (123-166) for patients who were administered ? 5 x 106/kg and < 5 x 106/kg of CD34+ HPC, respectively (p= 0.009). The increased amount of CD34+ autologous hematopoietic stem cell dose after high dose melphalan chemotherapy in MM patients shortens platelet and neutrophil engraftment time and increases overall survival. Early platelet engraftment and administration of CD34+ HPC count ? 5 x 106/kg can be considered as predictors of a better survival in patients.